title: IBD in 2010: optimizing treatment and minimizing adverse events.
abstract: The management of IBD remains a challenge, with the main issue being to combine therapeutic efficiency with minimal side effects and optimal quality of life. Efforts towards achieving this objective continued in 2010—we discuss some of the most relevant publications and their potential impact on daily practice in the future.
authors.affiliation: Service d'Hépato-Gastroentérologie, Center Hospitalier Jolimont-Lobbes, Rue Ferrer 159, Haine-Saint-Paul, Belgium.
authors.forename: Bénédicte
authors.initials: B
authors.lastname: De Vroey
authors.forename: Jean-Frédéric
authors.initials: JF
authors.lastname: Colombel
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D011788:Quality of Life; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D000069285:Infliximab; C456519:visilizumab; D001379:Azathioprine